Company Overview and News
Ameris Bancorp (ABCB - Free Report) has announced its plans to undertake cost-saving initiatives in a bid to lower annual operating expenses. As part of its efforts, the company intends to consolidate certain branches and trim data-processing fees. These efforts will help the bank slash costs by $20 million in 2019. These initiatives will enable Ameris Bancorp to reinvest the savings for achieving its long-term growth targets without impacting earnings in 2018 and 2019.
KBH IBTX AFCF FBMS INDB HMBH CBTX IBCP FIBH AMNB ABCB ACFC FBSI
2018-09-22 seekingalpha - 2
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
TCBK CAT MET HTH LBCC FIXX CRM BUSE STXB CHFC FIBH FBLV AVGO HBMD CAG SSB ABX MO SBT UMRX PRU MTZ NBHC HOMB EVRI 2914 FFIN BILI OPBK TAP ABRW OZK ACB BREW UNUM OLBK MTN JNJ GHG ALDX BWA VZ FNV EQBK LMT FB JAPAF RAD FNLC AXP 4162 ITYBF PRU CBTX JAPAY PPBI SFNC PNFP TBK CCL KO NCOM NBHOZ CARO TSC BOFIL KBH LION SPPI SMBK PACW DY LTEA BB WSBC TTEC VBTX ABCB DTEA HBNC GNPX FBPRM FBPRL FBPRO XLC FBPRN SNDX CSFL FBPRP MBIN HTWC AZN KMX ACBFF GBCI BATS SIVB KEY BOKF ASNA ABTX HTLF NKE HON TWTR AMAT CELH ROX JBL FBP IMBBY BY CHCO KDP INCY CRON FSB CCL STZ NBEV WTFCW WTFC FBMS WTFCM INTU NBHDZ GOOGL EGBN LTXB STL FBNC BA BB ONB PRGS FBK PFE IMBBF PFBC PH NEM LOXO MNST GOOG PIR RBB TLRY HWC PB BFST NCBS MKC WEED ACN FBSI BBBY DIS BMY OBNK OGE MBNC RNST ABX BOFI CMCSA SNV UBSH WTFPP CGC CADE AZN T IBOC IQ ONE MRK GNTY
Although organic loan growth was a little sluggish in the second quarter, the overall pace of growth for First Bancshares remains robust, with healthy spreads from a low deposit beta.
FIBH SSNF FBSI FBMS
On Sep 14, the yield on benchmark 10-year U.S. Treasury Note crossed 3%. The increase in government bond yield can primarily be attributed to expectations of higher economic growth in the third quarter of 2018. Moreover, job market data for August revealed a significant surge in the hourly wage rate which has once again fanned inflationary apprehensions. Strong fundamentals of the U.S. economy may lead to higher interest rated either in the form of Fed rate hike or higher yields on government bonds.
FAM BHBK BPOP FBMS BPOPP FIBH BPOPO NRIM BMRC BPOPM FBSI BPOPN
MOUNTAIN GROVE, Mo., Aug. 31, 2018 (GLOBE NEWSWIRE) -- First Bancshares, Inc. (OTCPink - FstBksh: FBSI), the holding company for Stockmens Bank (“Bank”), today announced that the Company’s Board of Directors authorized the repurchase of an aggregate of 25,000 shares of the Company’s common stock. The repurchase program will be commenced immediately and will be funded by the Company's available cash.
FIBH FBSI FBMS
The first half of 2018 has turned out to be highly profitable for the U.S. banking sector. In the second quarter of 2018, total profit of the banks topped prior record set in the preceding quarter. Moreover, U.S. banks are set to benefit significantly from expected hike in interest rate by the Fed in September. At this stage, it will be a prudent move to invest in bank stocks with favorable Zacks Rank and strong growth potential.
FAM BHBK BPOP FBMS NWL BPOPP FIBH BPOPO BCML NRIM BPOPM FBSI BPOPN
Cost of living for Americans rose in July at the fastest pace in a decade, indicating a strong U.S. economy and tighter labor market. Shelter costs gave a big boost to results, implying that the Fed's gradual interest rate hike will be on track.
BRK.A FAM PVG FIBH LADR ARI PVG FBSI FBMS
Greetings and welcome to the StoneCastle Financial Corp. Second Quarter Financial Release Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
FIBH FBSI BANX FBMS
MOUNTAIN GROVE, Mo., July 13, 2018 (GLOBE NEWSWIRE) -- First Bancshares, Inc. (OTCPink:FBSI), the holding company for Stockmens Bank (“Bank”), today announced its financial results for the quarter ended June 30, 2018.
FIBH FBSI FBMS
MOUNTAIN GROVE, Mo., April 27, 2018 (GLOBE NEWSWIRE) -- First Bancshares, Inc. (OTCQB:FBSI), the holding company for Stockmens Bank (“Bank”), today announced its financial results for the quarter ended March 31, 2018.
FIBH FBSI FBMS
First Bancshares, Inc. (“Company”) (OTCQB:FBSI), the holding company for Stockmens Bank, Colorado Springs, Colorado today announced the Company’s financial results for the quarter and year ended December 31, 2017.
FIBH FBSI FBMS
5h - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
as of ET